Advanced Filters
noise
Found 811 clinical trials
F Felicia Kwan

Levetiracetam for Persons at Risk for Alzheimer's Disease

The goal of this clinical trial is to investigate whether very small doses of a drug called levetiracetam (LEV) may reduce abnormal brain signaling in individuals who are at an increased risk for developing Alzheimer's Disease (AD). The study is looking for individuals who have a parent or sibling with …

55 - 85 years of age All Phase 2
R Raeghan Mueller

CBD for Individuals at Risk for Alzheimer's Disease

This is a double-blind, randomized controlled trial designed to test the effects of cannabidiol (CBD) on validated biomarkers of Alzheimer's disease (AD) progression, and behavioral, neurocognitive, and clinical measures, with putative mechanisms of action.

55 - 85 years of age All Phase 2
K Kathy Xie, PhD

Mindfulness for Cognition in Early-stage Alzheimer's Disease

The goal of this clinical trial is to learn if mindfulness meditation can improve outcomes in older adults with and without cognitive impairment. The main questions it aims to answer are: How does mindfulness impact thinking and memory? How does mindfulness influence brain function and structure? How does mindfulness affect …

50 - 100 years of age All Phase N/A
W Wenjing Jiang

Application of AI Technology for the Diagnosis and Treatment of Geriatric Diseases

1\) Characteristics of handwriting, gait, speech, eye movements, biological samples (blood, urine, stool, saliva, etc.), images, EEG, and other relevant markers in patients with Alzheimer's disease. (2) Characteristics of handwriting, gait, language, eye movement, biological samples (blood, urine, stool, saliva, etc.), imaging, EEG, and other relevant markers in patients with …

8 - 100 years of age All Phase N/A
D Dennis Yang, MD

Evaluation of the Clinical Utility of Endoscopic Closure Using a Dual Action Tissue (DAT) Clip

This study is designed as a multicenter prospective data recording study to document the performance of the DAT clip as part of standard medical care of patients. No experimental interventions will be performed.

18 years of age All Phase N/A
B Barbara Poletti, Ph.D

Advances in Telephone-based Cognitive Screening Procedures

Background Cognitive screening procedures via performance-based tests represent an essential, albeit preliminary, element within the diagnostic and interventional process as addressed to patients with chronic neurological disorders. Furthermore, in these populations, cognitive screening measures are often employed as outcomes in epidemiological settings, as well as endpoints in clinical trials. Therefore, …

18 - 100 years of age All Phase N/A
C Claudia Clementi

Improving Prognostic Confidence in Neurodegenerative Diseases Causing Dementia Using Peripheral Biomarkers and Integrative Modeling

To develop a model to predict disease progression in a large cohort of patients across a variety of neurodegenerative diseases, including Mild Cognitive Impairment (MCI) and dementia due to any neurodegenerative disease, including Alzheimer's Disease (AD), Lewy Body Disease (LBD), Vascular Disease (VaD) and Frontotemporal lobar degeneration (FTLD).

30 - 95 years of age All Phase N/A
y yuanjiao yan, PhD

Cognitive Leisure and Preclinical Alzheimer's Disease: Exploring Neural Mechanisms

The goal of this clinical trial is aims to: Translate and culturally adapt the Cognitive Leisure Activity Scale (CLAS) into Chinese and Conduct reliability and validity tests for the Chinese version of CLAS. Investigate the correlation between cognitive leisure activity levels and cognitive function in the preclinical stage of Alzheimer's …

60 years of age All Phase N/A
D David Kersting, MD PhD

Cardiac Amyloid Deposits and Heart Dysfunction in Alzheimer's Disease

This study seeks to explore the possible common pathogenesis of both cardiac amyloidosis and Alzheimer's disease, which can both be associated with amyloid deposits. Using Positron Emission Tomography (PET) scans with amyloid tracers - a conventional tool for non-invasively imaging amyloid deposits in Alzheimer's disease - the research will extend …

18 years of age All Phase N/A
M Mariana Figueiro, PhD

Phase 2 - Rhythmic Light Therapy for Alzheimer's Disease Patients

Participants will randomly be placed into one of four groups and experience one of the four following conditions: (1) a placebo light that provides a 40 hertz (Hz) flicker (rhythmic light \[RL\]); (2) a placebo light with a random flicker (placebo condition for rhythmic light); (3) a light source that …

55 years of age All Phase N/A

Simplify language using AI